Skip to main content
    B

    Brainsway Ltd (BWAY)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $10.11
    -0.14 (-1.37%)

    Market Cap: $406.96M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    Brainsway Ltd (BWAY) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Brainsway (BWAY) trades at 27.8x trailing earnings and 3.4x sales. Its P/B of 2.7x is below its 5-year median of 3.5x. Its forward P/E is 13.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 105.9% higher over the next year. Its free cash flow yield is 4.3%.

    MultipleValue
    P/E (trailing)27.8x
    Forward P/E13.5x
    Price to sales3.4x
    Price to book2.7x
    Price to FCF23.4x
    PEGN/A
    FCF yield4.3%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B2.7x3.5xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 6 of the 7 year ends shown that have a P/S, its P/S ranged from 3.0x in 2022 to 11.2x in 2025. 2025 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$9.5176.8x11.2x5.4x
    2024$4.7270.7xN/A2.9x
    2023$3.24N/A8.4x2.6x
    2022$1.24N/A3.0x1.8x
    2021$3.85N/A5.4x2.2x
    2020$3.77N/A6.4x8.5x
    2019$4.88N/A4.9x9.0x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BWAY

    What is BWAY's forward P/E ratio?

    Brainsway has a forward P/E ratio of 13.5x.

    Is BWAY stock overvalued?

    GNG's valuation label for BWAY is Undervalued.

    What is BWAY's price to sales ratio?

    Brainsway has a price to sales ratio of 3.4x.